These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37639777)

  • 1. Gaboxadol in angelman syndrome: A double-blind, parallel-group, randomized placebo-controlled phase 3 study.
    Keary C; Bird LM; de Wit MC; Hatti S; Heimer G; Heussler H; Kolevzon A; Mathews A; Ochoa-Lubinoff C; Tan WH; Yan Y; Adams M
    Eur J Paediatr Neurol; 2023 Nov; 47():6-12. PubMed ID: 37639777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The STARS Phase 2 Study: A Randomized Controlled Trial of Gaboxadol in Angelman Syndrome.
    Bird LM; Ochoa-Lubinoff C; Tan WH; Heimer G; Melmed RD; Rakhit A; Visootsak J; During MJ; Holcroft C; Burdine RD; Kolevzon A; Thibert RL
    Neurology; 2021 Feb; 96(7):e1024-e1035. PubMed ID: 33443117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
    Nasser A; Hull JT; Chaturvedi SA; Liranso T; Odebo O; Kosheleff AR; Fry N; Cutler AJ; Rubin J; Schwabe S; Childress A
    CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 2-week efficacy and safety study of gaboxadol and zolpidem using electronic diaries in primary insomnia outpatients.
    Hajak G; Hedner J; Eglin M; Loft H; Stórustovu SI; Lütolf S; Lundahl J;
    Sleep Med; 2009 Aug; 10(7):705-12. PubMed ID: 19346160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
    Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
    J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of gaboxadol on patient-reported measures of sleep and waking function in patients with Primary Insomnia: results from two randomized, controlled, 3-month studies.
    Roth T; Lines C; Vandormael K; Ceesay P; Anderson D; Snavely D
    J Clin Sleep Med; 2010 Feb; 6(1):30-9. PubMed ID: 20191935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD).
    Wigal TL; Newcorn JH; Handal N; Wigal SB; Mulligan I; Schmith V; Konofal E
    CNS Drugs; 2018 Mar; 32(3):289-301. PubMed ID: 29557078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized placebo controlled clinical trial to evaluate the efficacy and safety of minocycline in patients with Angelman syndrome (A-MANECE study).
    Ruiz-Antoran B; Sancho-López A; Cazorla-Calleja R; López-Pájaro LF; Leiva Á; Iglesias-Escalera G; Marín-Serrano ME; Rincón-Ortega M; Lara-Herguedas J; Rossignoli-Palomeque T; Valiente-Rodríguez S; González-Marques J; Román-Riechmann E; Avendaño-Solá C
    Orphanet J Rare Dis; 2018 Aug; 13(1):144. PubMed ID: 30126448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study.
    Asnis GM; Bose A; Gommoll CP; Chen C; Greenberg WM
    J Clin Psychiatry; 2013 Mar; 74(3):242-8. PubMed ID: 23561229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Lisdexamfetamine in Preschool Children With Attention-Deficit/Hyperactivity Disorder.
    Childress AC; Lloyd E; Jacobsen L; Gunawardhana L; Johnson SA; Findling RL
    J Am Acad Child Adolesc Psychiatry; 2022 Dec; 61(12):1423-1434. PubMed ID: 35577034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of the selective extrasynaptic GABA A agonist, gaboxadol, in a model of transient insomnia: a randomized, controlled clinical trial.
    Walsh JK; Mayleben D; Guico-Pabia C; Vandormael K; Martinez R; Deacon S
    Sleep Med; 2008 May; 9(4):393-402. PubMed ID: 17765013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder.
    Kasper S; Ebert B; Larsen K; Tonnoir B
    Int J Neuropsychopharmacol; 2012 Jul; 15(6):715-25. PubMed ID: 22008735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study.
    Kahn RS; Schulz SC; Palazov VD; Reyes EB; Brecher M; Svensson O; Andersson HM; Meulien D;
    J Clin Psychiatry; 2007 Jun; 68(6):832-42. PubMed ID: 17592906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An adapted clinical global Impression of improvement for use in Angelman syndrome: Validation analyses utilizing data from the NEPTUNE study.
    Ventola P; Jaeger J; Keary CJ; Kolevzon A; Adams M; Keshavan B; Zinger-Salmun C; Ochoa-Lubinoff C
    Eur J Paediatr Neurol; 2023 Nov; 47():35-40. PubMed ID: 37688937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
    O'B Hourihane J; Beyer K; Abbas A; Fernández-Rivas M; Turner PJ; Blumchen K; Nilsson C; Ibáñez MD; Deschildre A; Muraro A; Sharma V; Erlewyn-Lajeunesse M; Zubeldia JM; De Blay F; Sauvage CD; Byrne A; Chapman J; Boralevi F; DunnGalvin A; O'Neill C; Norval D; Vereda A; Skeel B; Adelman DC; du Toit G
    Lancet Child Adolesc Health; 2020 Oct; 4(10):728-739. PubMed ID: 32702315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.